[CITATION][C] VY-AADC01 in Medically Refractory Parkinson's Disease: Safety and Efficacy of a Phase 1b Dose-Ranging Study 12 Months and Beyond

CW Christine, PS Larson… - ANNALS OF …, 2018 - … ST, HOBOKEN 07030-5774, NJ USA
Save Cite Cited by 1 Related articles